PBS coverage means that Australians dealing with severe acne can access prescription medications like isotretinoin at significantly reduced prices, with general patients now paying a maximum of $25 per script and concession cardholders paying just $7.70. Since January 1, 2026, the PBS co-payment for general Medicare cardholders dropped from $31.60 to $25.00 — the lowest it has been since 2004 — making treatments for severe cystic acne more financially accessible than they have been in over two decades. For the roughly 21,000 Australians treated with isotretinoin each year, that reduction adds up quickly across a course of treatment that can span several months. But the PBS does not cover every acne medication equally, and not everyone qualifies for the subsidised price.
Isotretinoin, the most powerful acne drug available, requires an authority prescription and proof that conventional treatments have already failed. Spironolactone, while listed on the PBS, is typically used off-label for acne in women. This article breaks down which acne medications are covered, what the eligibility criteria actually look like in practice, how the 2026 co-payment changes affect your out-of-pocket costs, and what limitations you should be aware of before assuming the PBS will foot the bill. Understanding the gap between what is technically listed on the PBS and what you can actually access without jumping through hoops is the difference between affordable treatment and unexpected pharmacy bills.
Table of Contents
- Which Acne Medications Does the PBS Actually Cover?
- How the 2026 PBS Co-Payment Drop Changes What You Pay for Acne Scripts
- What It Takes to Qualify for PBS-Subsidised Isotretinoin
- Isotretinoin vs. Spironolactone — Comparing Your PBS-Covered Options
- Common Pitfalls and Gaps in PBS Acne Coverage
- How PBS Coverage Compares to Paying Full Price
- What Could Change for PBS Acne Coverage Going Forward
- Conclusion
- Frequently Asked Questions
Which Acne Medications Does the PBS Actually Cover?
The two main acne-related medications listed on the PBS are isotretinoin and spironolactone, but they serve very different purposes and come with different prescribing conditions. Isotretinoin — sold under brand names like Roaccutane and Oratane — is the heavy hitter. It is specifically listed for severe recalcitrant nodular acne that has not responded to conventional therapy, including courses of systemic antibiotics. This is not a first-line treatment. You cannot walk into a GP’s office with moderate breakouts and walk out with a PBS-subsidised isotretinoin script. The system is designed to reserve it for cases where other options have genuinely failed. Spironolactone, marketed as Aldactone, occupies an unusual position.
It is on the PBS, but its primary indication is not acne — it is a potassium-sparing diuretic originally developed for heart failure and hypertension. Doctors prescribe it off-label for acne in female patients because it reduces testosterone levels, which in turn reduces sebum production. Because it is already PBS-listed for its original indications, patients can access it at the subsidised price, but the prescribing context matters. Your doctor needs to navigate the PBS criteria carefully, and the off-label nature means the pathway is less straightforward than it is for isotretinoin. What the PBS does not cover is worth noting too. Over-the-counter topical treatments like benzoyl peroxide, adapalene gel, and salicylic acid products are not subsidised. Prescription topical retinoids and topical antibiotics may have some PBS listings, but the subsidies that make the biggest financial difference apply to the oral medications used for severe cases. If your acne is mild to moderate, the PBS is unlikely to change your costs in any meaningful way.
How the 2026 PBS Co-Payment Drop Changes What You Pay for Acne Scripts
The co-payment reform that took effect on January 1, 2026 reduced the maximum PBS co-payment from $31.60 to $25.00 per script for general Medicare cardholders. The Australian Government has framed this as the lowest PBS price since 2004, and it is projected to deliver $689 million in savings over four years across all PBS medicines, benefiting roughly 20 million Australians who do not hold a concession card. For someone on a standard course of isotretinoin, the savings are tangible but not transformative. A typical treatment course runs six to eight months, with monthly prescriptions. At the old rate of around $31.60 per script, that was roughly $190 to $253 over a full course. At $25.00 per script, that drops to $150 to $200.
The savings of $40 to $53 across a treatment course are real, but they are not going to change anyone’s decision about whether to pursue treatment. Where it matters more is for patients on multiple PBS medications simultaneously — someone managing acne alongside other conditions will feel the cumulative benefit across all their scripts. However, there is a catch that has gone underreported. The optional $1 pharmacist discount on PBS medicines was phased out for general Medicare cardholders from January 1, 2026. Some patients who were previously receiving this discount at participating pharmacies may find that the net reduction feels smaller than the headline $6.60 drop suggests. Concession cardholders continue to pay a maximum of $7.70 per script, with that rate frozen until 2030, so the 2026 changes primarily benefit those without a concession card.
What It Takes to Qualify for PBS-Subsidised Isotretinoin
The PBS does not subsidise isotretinoin for anyone who asks. The eligibility requirements are specific and strictly enforced. A patient must have severe recalcitrant nodular acne — the kind that produces deep, painful cysts and nodules, not just surface-level pimples or occasional breakouts. Beyond the diagnosis itself, the PBS requires evidence that the patient has failed conventional treatments, which explicitly includes at least one course of systemic antibiotics. In practice, this means most patients will have tried oral antibiotics like doxycycline or minocycline, along with topical treatments, before isotretinoin becomes a PBS-eligible option. The prescription itself must be written as an authority prescription. This means the prescribing doctor — usually a dermatologist, though GPs can prescribe in some cases — needs to contact Services Australia or use the electronic authority system to obtain approval for the subsidised supply.
This is an extra administrative step that does not exist for standard PBS prescriptions, and it exists because isotretinoin is a potent drug with significant side effects, including its well-documented teratogenic risks. Female patients of childbearing age face additional requirements around pregnancy testing and contraception. For a concrete example, consider a 19-year-old university student in Melbourne with severe cystic acne across the jawline and back. They have spent the past year trying topical retinoids, benzoyl peroxide, and a three-month course of doxycycline without improvement. Their dermatologist documents these failed treatments, submits an authority prescription, and the PBS subsidises the isotretinoin. Without the PBS, a month’s supply of isotretinoin could cost significantly more out of pocket. With it, they are paying $25 or $7.70 depending on their card status. That said, if this same student had only tried topical treatments and skipped the antibiotic step, they would not yet meet the PBS criteria regardless of how severe their acne appeared.
Isotretinoin vs. Spironolactone — Comparing Your PBS-Covered Options
The choice between isotretinoin and spironolactone is not simply about preference — it depends on your sex, the type of acne you have, and how your body responds to hormonal factors. Isotretinoin is available to all patients regardless of sex and targets acne at its source by shrinking sebaceous glands and dramatically reducing oil production. A single course has been shown to result in complete and prolonged remission in many patients, which is why dermatologists often describe it as the closest thing to a cure for severe acne. The tradeoff is a significant side effect profile: severe dryness, potential mood changes, mandatory blood monitoring, and absolute contraindication in pregnancy. Spironolactone works through a completely different mechanism and is only prescribed for acne in female patients. By blocking androgen receptors and reducing testosterone levels, it addresses the hormonal component driving breakouts, particularly along the jawline and chin.
It does not carry the same intensity of side effects as isotretinoin, but it is also not a one-course solution. Most women who benefit from spironolactone for acne need to continue taking it long-term, and acne often returns when the medication is stopped. From a cost perspective, both medications are available at the PBS-subsidised rate, so the financial difference is negligible — the clinical considerations should drive the decision. The limitation worth flagging is that spironolactone’s off-label status for acne means some GPs are less comfortable prescribing it for this purpose, and the PBS listing technically covers its cardiovascular indications. While pharmacies will dispense it at the PBS price regardless of the clinical reason, some patients report confusion or pushback at the prescribing stage. If your doctor is unfamiliar with its use in dermatology, a referral to a dermatologist who regularly prescribes it for hormonal acne may smooth the process.
Common Pitfalls and Gaps in PBS Acne Coverage
One of the most frequent frustrations patients encounter is the assumption that a PBS listing means automatic access. The authority prescription requirement for isotretinoin introduces a gatekeeping step that can slow down treatment initiation, particularly for patients in rural or regional areas where dermatologist wait times can stretch to months. A GP can prescribe isotretinoin, but many are reluctant to do so given the monitoring requirements and potential liability, effectively funnelling patients into an already-strained specialist system. Another gap is that the PBS does not cover the ancillary costs of isotretinoin treatment. Monthly blood tests to monitor liver function and lipid levels are standard practice during a course, and while Medicare covers some pathology, patients may still face out-of-pocket costs depending on whether their pathology provider bulk-bills.
The dermatologist appointments themselves are another expense — the Medicare rebate for a specialist consultation rarely covers the full fee, leaving a gap that can run $50 to $150 per visit depending on the practitioner and location. Over a six-month course, these associated costs can exceed the medication cost itself, even at the pre-2026 co-payment rate. There is also the question of repeat courses. While a single course of isotretinoin produces lasting remission for many patients, some experience relapse and require a second or even third course. Each new course requires a fresh authority prescription and, in some cases, re-establishing that the acne meets severity criteria. The PBS does not limit the number of courses a patient can receive, but the administrative burden resets each time, and some prescribers take a more conservative approach to repeat courses than to initial treatment.
How PBS Coverage Compares to Paying Full Price
Without PBS subsidisation, isotretinoin is not prohibitively expensive compared to some other medications, but the difference is still meaningful. Private pricing for a month’s supply of isotretinoin varies by brand, dose, and pharmacy, but generally ranges from $40 to $80 or more without the subsidy. Over a six-month course, that puts the unsubsidised total somewhere between $240 and $480, compared to $150 to $200 at the current PBS co-payment rate for general patients, or as little as $46.20 for the entire course if you hold a concession card.
Where the PBS pricing becomes genuinely significant is for concession cardholders — students with a Health Care Card, pensioners, and others eligible for the $7.70 rate. For these patients, a full course of isotretinoin costs less than a single unsubsidised script would. Given that severe cystic acne disproportionately affects adolescents and young adults, many of whom qualify for concession pricing through Youth Allowance or Austudy, the PBS effectively removes cost as a barrier to the most effective treatment available for their condition.
What Could Change for PBS Acne Coverage Going Forward
The 2026 co-payment reduction signals a broader government appetite for making PBS medicines more affordable, and the freeze on concession card co-payments through 2030 provides stability for the most financially vulnerable patients. Whether further reductions to the general co-payment are on the horizon remains to be seen, but the political momentum behind “cheaper medicines” messaging suggests prices are unlikely to increase in the near term. The more interesting space to watch is whether newer acne treatments will earn PBS listings.
Several novel therapies targeting different pathways in acne development are in various stages of clinical trials and regulatory review globally. If any of these reach the Australian market and secure a PBS listing, the treatment landscape could shift meaningfully. For now, though, isotretinoin remains the gold standard for severe acne, and the PBS framework — despite its bureaucratic requirements — ensures that cost alone does not prevent Australians from accessing it.
Conclusion
PBS coverage for acne treatment in Australia is most impactful for patients with severe cystic acne who qualify for subsidised isotretinoin. The 2026 co-payment reduction to $25 per script for general Medicare cardholders, down from $31.60, brings PBS medicines to their lowest price in over two decades. Combined with the $7.70 concession rate frozen until 2030, the financial barrier to isotretinoin has never been lower. Spironolactone offers an additional PBS-accessible option for women with hormonally driven acne, though its off-label status adds a layer of complexity.
The practical next step for anyone considering PBS-subsidised acne treatment is to have an honest conversation with their doctor about treatment history. If you have already tried and failed conventional therapies including antibiotics, you likely meet the criteria for PBS-subsidised isotretinoin. If you have not yet gone through those steps, the PBS framework requires that you do so first. Factor in the costs beyond the script itself — blood tests, specialist appointments, and the time commitment of monthly monitoring — so there are no surprises once treatment begins.
Frequently Asked Questions
Do I need to see a dermatologist to get PBS-subsidised isotretinoin?
Not necessarily. GPs can prescribe isotretinoin with an authority prescription, but many prefer to defer to dermatologists due to the monitoring requirements and side effect profile. In practice, most patients end up seeing a specialist.
Can men get spironolactone on the PBS for acne?
Spironolactone is not prescribed for acne in male patients. Its anti-androgen effects can cause breast tissue growth and other feminising side effects in men, making it unsuitable for this purpose regardless of PBS listing.
How long does a typical course of isotretinoin last?
Most courses run between five and eight months, depending on the dose and severity of acne. Some patients achieve remission sooner, while others may need a longer or repeated course.
Will the PBS cover my acne treatment if I only have mild breakouts?
No. PBS-subsidised isotretinoin is reserved for severe recalcitrant nodular acne that has not responded to conventional treatments. Mild to moderate acne does not meet the eligibility criteria, and most topical acne treatments are not PBS-subsidised.
Has the $1 pharmacist discount been removed?
For general Medicare cardholders, yes. The optional $1 pharmacist discount on PBS medicines was phased out from January 1, 2026. This means the $25 co-payment is the actual price at the counter — there is no additional discount available from the pharmacy.
Can I get isotretinoin on the PBS if antibiotics gave me side effects but I did not complete the full course?
This is a grey area. The PBS criteria require that conventional therapy including systemic antibiotics has been tried and failed. If you experienced a documented adverse reaction to antibiotics that prevented you from completing treatment, your prescribing doctor may be able to argue this satisfies the requirement, but it is at their discretion and subject to approval through the authority process.
